These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 26296701)

  • 1. Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy.
    Ellingson MS; Hart SN; Kalari KR; Suman V; Schahl KA; Dockter TJ; Felten SJ; Sinnwell JP; Thompson KJ; Tang X; Vedell PT; Barman P; Sicotte H; Eckel-Passow JE; Northfelt DW; Gray RJ; McLaughlin SA; Moreno-Aspitia A; Ingle JN; Moyer AM; Visscher DW; Jones K; Conners A; McDonough M; Wieben ED; Wang L; Weinshilboum R; Boughey JC; Goetz MP
    Breast Cancer Res Treat; 2015 Sep; 153(2):435-43. PubMed ID: 26296701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
    Tung N; Lin NU; Kidd J; Allen BA; Singh N; Wenstrup RJ; Hartman AR; Winer EP; Garber JE
    J Clin Oncol; 2016 May; 34(13):1460-8. PubMed ID: 26976419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.
    Spugnesi L; Gabriele M; Scarpitta R; Tancredi M; Maresca L; Gambino G; Collavoli A; Aretini P; Bertolini I; Salvadori B; Landucci E; Fontana A; Rossetti E; Roncella M; Naccarato GA; Caligo MA
    Genes Chromosomes Cancer; 2016 Dec; 55(12):915-924. PubMed ID: 27328445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer.
    Lin PH; Kuo WH; Huang AC; Lu YS; Lin CH; Kuo SH; Wang MY; Liu CY; Cheng FT; Yeh MH; Li HY; Yang YH; Hsu YH; Fan SC; Li LY; Yu SL; Chang KJ; Chen PL; Ni YH; Huang CS
    Oncotarget; 2016 Feb; 7(7):8310-20. PubMed ID: 26824983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer.
    Rummel SK; Lovejoy L; Shriver CD; Ellsworth RE
    Breast Cancer Res Treat; 2017 Aug; 164(3):593-601. PubMed ID: 28503720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer.
    Maxwell KN; Wubbenhorst B; D'Andrea K; Garman B; Long JM; Powers J; Rathbun K; Stopfer JE; Zhu J; Bradbury AR; Simon MS; DeMichele A; Domchek SM; Nathanson KL
    Genet Med; 2015 Aug; 17(8):630-8. PubMed ID: 25503501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.
    Li J; Meeks H; Feng BJ; Healey S; Thorne H; Makunin I; Ellis J; ; Campbell I; Southey M; Mitchell G; Clouston D; Kirk J; Goldgar D; Chenevix-Trench G
    J Med Genet; 2016 Jan; 53(1):34-42. PubMed ID: 26534844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
    Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR
    Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer.
    Hart SN; Ellingson MS; Schahl K; Vedell PT; Carlson RE; Sinnwell JP; Barman P; Sicotte H; Eckel-Passow JE; Wang L; Kalari KR; Qin R; Kruisselbrink TM; Jimenez RE; Bryce AH; Tan W; Weinshilboum R; Wang L; Kohli M
    BMJ Open; 2016 Apr; 6(4):e010332. PubMed ID: 27084275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of novel germline mutations in six breast cancer predisposition genes by targeted next-generation sequencing.
    Dong L; Wu N; Wang S; Cheng Y; Han L; Zhao J; Long X; Mu K; Li M; Wei L; Wang W; Zhang W; Cao Y; Liu J; Yu J; Hao X
    Hum Mutat; 2018 Oct; 39(10):1442-1455. PubMed ID: 30039884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
    Seifert BA; O'Daniel JM; Amin K; Marchuk DS; Patel NM; Parker JS; Hoyle AP; Mose LE; Marron A; Hayward MC; Bizon C; Wilhelmsen KC; Evans JP; Earp HS; Sharpless NE; Hayes DN; Berg JS
    Clin Cancer Res; 2016 Aug; 22(16):4087-4094. PubMed ID: 27083775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
    Bonache S; Esteban I; Moles-Fernández A; Tenés A; Duran-Lozano L; Montalban G; Bach V; Carrasco E; Gadea N; López-Fernández A; Torres-Esquius S; Mancuso F; Caratú G; Vivancos A; Tuset N; Balmaña J; Gutiérrez-Enríquez S; Diez O
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2495-2513. PubMed ID: 30306255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.
    Girard E; Eon-Marchais S; Olaso R; Renault AL; Damiola F; Dondon MG; Barjhoux L; Goidin D; Meyer V; Le Gal D; Beauvallet J; Mebirouk N; Lonjou C; Coignard J; Marcou M; Cavaciuti E; Baulard C; Bihoreau MT; Cohen-Haguenauer O; Leroux D; Penet C; Fert-Ferrer S; Colas C; Frebourg T; Eisinger F; Adenis C; Fajac A; Gladieff L; Tinat J; Floquet A; Chiesa J; Giraud S; Mortemousque I; Soubrier F; Audebert-Bellanger S; Limacher JM; Lasset C; Lejeune-Dumoulin S; Dreyfus H; Bignon YJ; Longy M; Pujol P; Venat-Bouvet L; Bonadona V; Berthet P; Luporsi E; Maugard CM; Noguès C; Delnatte C; Fricker JP; Gesta P; Faivre L; Lortholary A; Buecher B; Caron O; Gauthier-Villars M; Coupier I; Servant N; Boland A; Mazoyer S; Deleuze JF; Stoppa-Lyonnet D; Andrieu N; Lesueur F
    Int J Cancer; 2019 Apr; 144(8):1962-1974. PubMed ID: 30303537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
    Hauke J; Hahnen E; Schneider S; Reuss A; Richters L; Kommoss S; Heimbach A; Marmé F; Schmidt S; Prieske K; Gevensleben H; Burges A; Borde J; De Gregorio N; Nürnberg P; El-Balat A; Thiele H; Hilpert F; Altmüller J; Meier W; Dietrich D; Kimmig R; Schoemig-Markiefka B; Kast K; Braicu E; Baumann K; Jackisch C; Park-Simon TW; Ernst C; Hanker L; Pfisterer J; Schnelzer A; du Bois A; Schmutzler RK; Harter P
    J Med Genet; 2019 Sep; 56(9):574-580. PubMed ID: 30979843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes.
    Kurian AW; Ward KC; Abrahamse P; Hamilton AS; Katz SJ
    JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33426465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center.
    Elliott E; Speare V; Coggan J; Espenschied C; LaDuca H; Yussuf AF; Burgess K; Gray P; Cobleigh M; Rao R; Patel J; Kuzel T; Buckingham LE; Usha L
    Cancer Rep (Hoboken); 2020 Dec; 3(6):e1287. PubMed ID: 32881420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double heterozygosity for germline mutations in BRCA1 and p53 in a woman with early onset breast cancer.
    Bell K; Hodgson N; Levine M; Sadikovic B; Zbuk K
    Breast Cancer Res Treat; 2014 Jul; 146(2):447-50. PubMed ID: 24916180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.